Baseline Troponin T level in stroke and its association with stress cardiomyopathy

Kai Liesirova1*, Eugenio Abela1*, Thomas Pilgrim2*, Laura Bickel3, Thomas Meinel1, Julia Meisterernst1, Verma Rajeev3, Hakan Sarikaya1, Mirjam R. Heldner1, Tomas Dobrocky2, Erick Siqueira3, Marwan El-Koussy3, Urs Fischer1, Jan Gralla3, Marcel Arnold1, Heinrich P. Matte1, Kety Hsieh3‡, Simon Jung1‡*

1 Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 2 Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 3 University Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern, Switzerland

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.

* simon.jung@insel.ch

Abstract

Background

Differential diagnosis of elevated high-sensitive Troponin T (hsTnT) in acute ischemic stroke includes myocardial infarction (MI) and neurogenic stunned myocardium (NSM). The aim of this study was to identify factors associated with baseline hsTnT levels and MI or NSM in acute ischemic stroke.

Methods

We studied 204 consecutive patients of the prospective acquired Bern Stroke Database with acute ischemic stroke diagnosed by brain MR. All patient histories and cardiac examinations were reviewed retrospectively. Volumetry of lesions on diffusion and perfusion weighted brain imaging (circular singular value decomposition, Tmax > 6 sec) was performed. Voxel based analysis was performed to identify brain areas associated with hsTnT elevation. Linear regression analysis was used to identify predictors of baseline hsTnT levels and myocardial infarction.

Results

Elevated hsTnT was observed in 58 of the 204 patients (28.4%). The mean age was 68.3 years in the normal hsTnT group and 69.7 years in the elevated hsTnT group. Creatinine (p < 0.001, OR 6.735, 95% CI 58.734–107.423), baseline NIHSS score (p = 0.029, OR 2.207, 95% CI 0.675–12.096), ST segment depression (p = 0.025, OR 2.259, 95% CI 2.419–35.838), and negative T waves in baseline ECG (p = 0.002, OR 3.209, 95% CI 13.007–54.564) were associated with hsTnT elevation, while infarct location and size were not. Coronary angiography was performed in 30 of the 204 patients (14.7%) and myocardial infarction was diagnosed in 7 of them (23.3%). Predictive factors for myocardial infarction could not be identified.
Conclusion
Elevated baseline baseline hsTnT was associated with NIHSS, creatinine, ST segment depression and inverted T waves, but not with stroke location or size. None of the factors was helpful to differentiate MI and NSM. Therefore, ancillary investigations such as coronary angiography, cardiac MRI or both may be needed to solve the differential diagnosis.

Introduction
About 18–20% of ischemic stroke patients show elevated high sensitive Troponin T (hsTnT) levels on admission [1–3]. Differential diagnosis includes renal failure, chronic heart failure, myocardial infarction (MI) and stress-related cardiomyopathies or so called neurogenic stunned myocardium (NSM). NSM, which is characterized by contraction band necrosis on the cellular level, can clinically be expressed by hsTnT elevation, electrocardiography (ECG) abnormalities (such as ST segment changes, T inversions and pathological Q waves), regional wall motion abnormalities and in its most extend as Takotsubo Cardiomyopathy. In some patients diagnostic differentiation between MI and NSM is straightforward using ECG and echocardiography, but in some patients differentiation is impossible due to overlapping diagnostic criteria (ST segment changes, T inversions and pathological Q waves, wall motion abnormalities).[4–7]

A common practice in many stroke centers is to consider slightly elevated hsTnT levels originating from the brain and highly elevated levels from the heart. However, this empirical assumption might not be accurate, because MI patients have an increased risk for stroke not only during the acute stage but also later on, when the cardiac wall lesions enhance the risk for thrombus formation.[8] Accordingly, stroke may occur after MI when enzyme levels are already decreasing or even normalized. Indeed, MI can be found in stroke patients with only marginally elevated hsTnT.[9] Therefore, MI may be underdiagnosed in patients with acute ischemic stroke and the question arises whether baseline hsTnT levels have any predictive value to differentiate NSM and MI.

Studies showing an association between brain areas that are thought to be involved in the pathogenesis of NSM in stroke and baseline hsTnT elevation suggest that baseline hsTnT and stroke location might potentially differentiate between and MI, but results so far have been conflicting.[10–14] In a case control study, Ay and coworkers found the right posterior, superior, and medial insula and the right inferior parietal lobe to be associated with hsTnT elevation.[10] Unlike Ay et al, Laowattana and coworkers reported that left insular stroke was associated with an increased risk of adverse cardiac outcome and decreased cardiac wall motion compared to stroke in other locations and TIA.[15] Sykora et al demonstrated that baroreflex impairment in acute stroke is associated with insular involvement, left and right.[16] Beside the parts of the limbic system the rostral ventrolateral medulla [17], solitary tract nucleus, and intermediolateral cell column are thought to be brain areas that are potentially prone to produce NSM.[5]

The aim of this study was to identify baseline characteristics, laboratory parameters, ECG findings and imaging parameters (size and location of stroke) that are associated with baseline hsTnT levels and MI in a large cohort of acute ischemic stroke patients and to address the clinical question whether baseline hsTnT levels are helpful to differentiate between NSM and MI.
Patients and methods

Demographic data and review of cardiac history and examinations

This study is based on the Bernese stroke registry, a prospectively collected database of all patients with acute stroke admitted to our stroke center. Some aspects have been reported previously.[18–21]

All acute stroke patients between 2011 and 2014 were included in the analysis if 1) stroke was diagnosed by MRI on admission 2) and if hsTnT and ECG were performed on admission in the emergency department.

Age, gender, medication, baseline National Institutes of Health Stroke Scale (NIHSS), time from symptom onset to treatment, atrial fibrillation, hypertension, diabetes, smoking, hypercholesterolemia, history of ischemic stroke, known prior myocardial infarction, known coronary heart disease, prior medication, stroke treatment details such as intravenous thrombolysis or endovascular treatment and complications were recorded prospectively as baseline characteristics.

Laboratory changes during hospitalization, ECG findings and echocardiographic studies, and—if performed—coronary angiographies were systematically reviewed (K.L., T.P.) in all included patients. Myocardial infarction was suspected in case of a characteristic rise and fall of creatinine kinase MB fraction or hsTnT in combination with at least one of the following: ischemic symptoms, new pathologic Q-waves, or ischemic electrocardiographic changes. In addition, MI was only suspected if an underlying higher grade coronary stenosis or culprit lesion was found in coronary angiography.

The study was approved by the local ethics committee of Bern. Data were anonymized after data collection.

MRI methods and image analysis

Pre-treatment MRI was performed using a 1.5T or 3T MR imaging system (Magnetom, Siemens). The MRI protocol included whole brain DWI (b = 1000t, 24 slices, thickness 5 mm, TR 3200ms, TE 87ms, number of averages 2, matrix 256×256) yielding isotropic b0 and b1000 as well as apparent diffusion coefficient (ADC) maps that were calculated automatically. Volume-try of lesions on diffusion and perfusion weighted imaging (circular singular value decomposition, Tmax >6sec) was performed with the FDA approved software Olea Sphere (Olea Medical) (K.H., M.E.K.).

Voxel-based lesion-symptom mapping was used to identify neuroanatomical regions associated with elevated hsTnT levels. Binary lesion masks were generated from the DWI data by manual segmentation using MRICroN imaging software (https://www.nitrc.org/projects/mricron/). These masks were then normalized according to localization using standard Montreal Neurological Institute (MNI) space with SPM12 (http://www.fil.ion.ucl.ac.uk/spm/).

Assessed parameters

The following parameters were assessed (from database or by retrospective reviewing of patient history): age, gender, baseline NIHSS score, blood pressure on admission, blood markers on admission (hsTnT, CK, CK-MB, Creatinine), arterial hypertension, atrial fibrillation, prior myocardial infarction, coronary heart disease, prior medication (antiplatelet agents, anticoagulants, antihypertensive drugs, beta-blockers, statins), hypercholesterolemia, diabetes, smoking, prior stroke or TIA, diffusion restricted volume, hypoperfusion volume, perfusion-to-diffusion mismatch ratio, ECG changes on admission (ST-elevation/depression, T-negativity, pathological Q-wave, left/right bundle branch block, incomplete right bundle branch block, left anterior fascicular block) and echocardiographic abnormalities (wall motion.
abnormalities, left atrial and left ventricular thrombi). hsTnT was measured with Elektro-ChemiLumiszenImmunoAssay (ECLIA) from Roche (cutoff ≤0.014 μg/l).

Statistical analysis
Statistical analysis was performed using SPSS 21 (SPSS Inc., Chicago, Illinois, USA). Bivariate analysis of categorical variables was performed with χ² and Fisher’s exact test as appropriate and continuous variables with Mann-Whitney test. Non-normally distributed variables were transformed with the best method achieving near normal distribution (rang transformation for hsTnT, log transformation for Creatinine, and square root transformation for NIHSS). Linear regression with inclusion of all parameters which showed at least a trend for an association (p<0.2) was used to determine the predictors of hsTnT elevation and MI. A p-value < 0.05 was considered significant.

Association between baseline hsTnT and lesion load at each voxel was tested with two mass-univariate general-linear models: first, by an independent-samples t-test between patients with elevated and non-elevated hsTnT, and second, by regression of hsTnT against lesion load. Both models included total lesion volume as a nuisance variable. Only voxels lesioned in at least 2 subjects were included. Significance was tested using permutation tests in NiiStat (https://www.nitrc.org/projects/niostat/), i.e. by deriving an empirical distribution of T-values across all voxels and testing the probability of the original value against this distribution. We used 4000 permutations and considered a voxel statistically significant if its value survived a False-Discovery Rate (FDR) corrected threshold of p<0.05.

Results
A total of 204 consecutive patients with ischemic stroke were included in this study. Elevated hsTnT was observed in 58 of the 204 patients (28.4%). Mean hsTnT levels were 0.063 μg/l (SD 0.628) in all patients and 0.209 μg/l SD 1.172) in those with elevated hsTnT above the 99th percentile (> 0.014 μg/l). Transthoracic echocardiography was performed in 41 patients and transesophageal echocardiography in 95 patients.

Baseline characteristics and the results of univariable analysis for association with baseline hsTnT are shown in Table 1. All variables with p<0.2 were entered in linear regression analysis. Linear regression analysis revealed Creatinine (p<0.001, OR 6.735, 95% CI 58.734–107.423), NIHSS (p = 0.029, OR 2.207, 95% CI 0.675–12.096), ST segment depression (p = 0.025, OR 2.259, 95% CI 2.419–35.838), and negative T waves in baseline ECG (p = 0.002, OR 3.209, 95% CI 13.007–54.564) to be independently associated with hsTnT elevation (Table 2). The DWI lesion volume remained in the model until NIHSS was added to the analysis. When atrial fibrillation was included in the model, it turned out as independent predictor (p = 0.015, OR 2.475, 95% CI 4.977–45.574) and ST segment depression dropped out. The strength of this latter model was weaker, probably due to a significant dropout of patients (atrial fibrillation status was documented only in 100 of the 204 patients).

Coronary angiography was performed in 30 of the 204 patients (14.7%). After reviewing all available data MI was diagnosed definitely in 7 of the 30 patients (23.3%). Predictive factors for MI could not be identified.

MRI quality was sufficient for voxel-based analysis in 149 patients. A lesion overlap map is shown in Fig 1. Voxel-based lesion-symptom mapping failed to reveal unique lesion-hsTnT associations. In neither the categorical comparison of patients with and without elevated hsTnT nor the direct regression between hsTnT-values and lesion masks did any voxel survive the prespecified statistical threshold. Subgroup analysis with exclusion of patients with elevated creatinin failed to reveal unique lesion-hsTnT associations as well.
Table 1. Baseline characteristics of 204 acute stroke patients. P values of univariable analysis association with baseline hsTnT as continuous variable.

|                                | Patients without hsTnT elevation (n = 146) | Patients with hsTnT elevation (n = 58) | p     |
|--------------------------------|------------------------------------------|---------------------------------------|-------|
| Age                            | 68.3±13.5                                 | 69.7±13.1                             | 0.537 |
| Male gender                    | 94/146 (64.4%)                            | 41/58 (70.7%)                         | 0.924 |
| NIHSS base score               | 7.1±6.3                                   | 10±4.9                                | <0.001|
| Atrial fibrillation in long-term ECG monitoring | 27/67 (40.3%)                             | 18/33 (54.5%)                        | 0.051 |
| Prior MI                       | 5/86 (5.8%)                               | 7/30 (23.3%)                          | <0.001|
| Coronary artery disease        | 13/146 (8.9%)                             | 17/58 (29.3%)                         | <0.001|
| Prior stroke                   | 6/89 (6.7%)                               | 5/37 (13.5%)                          | 0.130 |
| Diabetes                       | 22/145 (15.2%)                            | 15/58 (25.9%)                         | 0.006 |
| Hypertension                   | 98/146 (67.1%)                            | 45/58 (77.6%)                         | 0.040 |
| Hypercholesterolaemia          | 84/146 (57.5%)                            | 34/58 (58.6%)                         | 0.672 |
| Smoking                        | 33/144 (22.9%)                            | 9/57 (15.8%)                          | 0.978 |
| Antiplatelets/oral anticoagulation use | 62/146 (42.5%)                            | 38/58 (65.5%)                         | <0.001|
| Statin drug use                | 35/146 (24.0%)                            | 22/56 (39.3%)                         | 0.018 |
| Antihypertensive drug use      | 67/146 (45.9%)                            | 40/57 (70.2%)                         | <0.001|
| Betablocker use                | 39/146 (26.7%)                            | 19/58 (32.8%)                         | 0.036 |
| BP systolic                    | 162.7±29.7                                | 106.7±31.3                            | 0.060 |
| BP diastolic                   | 80.1±17.7                                 | 85.8±25.7                             | 0.001 |

Laboratory parameters

|                                |                          |                                      |
|--------------------------------|--------------------------|-------------------------------------|
| Creatinine baseline            | 80.1±17.7                | 106.0±42.1                          | <0.001|

ECG Parameters

|                                |                          |                                      |
|--------------------------------|--------------------------|-------------------------------------|
| ECG ST-depression              | 35/146 (24.0%)           | 18/57 (31.6%)                       | 0.072 |
| ECG ST-elevation               | 10/146 (6.8%)            | 5/57 (8.8%)                         | 0.079 |
| ECG T-negative wave            | 16/146 (11.0%)           | 12/57 (21.1%)                       | 0.009 |
| ECG pathological Q-wave        | 25/146 (17.1%)           | 17/57 (29.8%)                       | 0.224 |
| ECG Left bundle branch block   | 2/146 (1.4%)             | 2/57 (3.5%)                         | 0.179 |
| ECG Right bundle branch block  | 6/146 (4.1%)             | 3/57 (5.3%)                         | 0.342 |
| ECG incomplete right bundle branch block | 1/146 (0.7%) | 0/57 (0.0%) | -       |
| ECG left anterior fascicular block | 5/146 (3.4%)           | 3/57 (5.3%)                         | -     |

Echocardiography parameters

|                                |                          |                                      |
|--------------------------------|--------------------------|-------------------------------------|
| Ventricular wall motion abnormalities | 16/105 (15.2%)         | 11/27 (40.7%)                       | 0.006 |
| Left atrial thrombus            | 3/108 (2.8%)             | 0                                   | 1.0   |
| Left ventricular thrombus       | 1/106 (0.9%)             | 0                                   | 1.0   |

MRI Parameters

|                                |                          |                                      |
|--------------------------------|--------------------------|-------------------------------------|
| MRI diffusion restricted volume in ml | 13.6±27.8            | 14.9±19.1                           | 0.358 |
| MRI perfusion restricted volume in ml | 50.1±57.3             | 66.9±74.5                           | 0.193 |
| MRI perfusion/diffusion mismatch ratio | 10.2±15.1             | 5.7±7.6                             | 0.910 |

Table 2. Independent predictors of baseline hsTnT elevation.

|                                | OR   | p     | 95% CI          |
|--------------------------------|------|-------|-----------------|
| Dependent variable: baseline hsTnT |      |       |                 |
| Creatinine                     | 6.735| <0.001| 58.734–107.423  |
| NIHSS                          | 2.207| 0.029 | 0.675–12.096    |
| ECG ST-depression              | 2.259| 0.025 | 2.419–35.838    |
| ECG negative T wave            | 3.209| 0.002 | 13.007–54.564   |

https://doi.org/10.1371/journal.pone.0209764.t001

https://doi.org/10.1371/journal.pone.0209764.t002
Discussion

The main finding of our study is that baseline hsTnT is probably not a suitable marker to differentiate MI and NSM in patients with acute ischemic stroke. The NIHSS score was associated with baseline hsTnT, which may suggest some impact of NSM on hsTnT. Nevertheless, we did not identify any predictors of MI that help to differentiate between MI or NSM as potential reasons of hsTnT elevation. hsTnT elevation was associated with ST segment depression and negative T waves in ECG, both of which can result of MI or NSM.

Overall, 28.4% of stroke patients included in this analysis had elevated hsTnT at baseline. In accordance with previous studies, we identified renal failure to be associated with hsTnT elevation.[13,22] In addition, ST segment depression and negative T waves on baseline ECG were associated with hsTnT elevation. As both MI and NSM can be accompanied by ST segment depression and negative T waves, these ECG findings do not help to differentiate between the two etiologies.[4,5] In accordance with previous studies hsTnT elevation and stroke severity as measured by NIHSS scores were also associated [11,12,23,24]. However, in our study unlike in previous investigations, neither the size of diffusion restriction nor the size of perfusion deficit in Tmax maps, was associated with hsTnT.[6] Because NIHSS scores are influenced both by

![Lesion overlap map.](https://doi.org/10.1371/journal.pone.0209764.g001)
infarct size and location, it might be that infarct location is more important for NSM development than infarct size. Indeed, several brain areas have been shown to be involved in the development of NSM, especially the insular cortex but also some brain stem areas. Nevertheless, whether baseline hsTnT elevation is associated with any infarct location remains uncertain, because study results are conflicting: three studies described involvement of the right insular cortex and right inferior parietal lobe to be associated with baseline hsTnT elevation,[10–12] but other studies did not.[13,14] In our detailed voxel based analysis we did not find any association of infarct location with baseline hsTnT. Interestingly, a recent study found an association of infarct location with temporal changes of hsTnT but not with baseline hsTnT.[14]

Only seven of our 30 patients who underwent coronary angiography were diagnosed to have suffered from MI, indicating that a high proportion of hsTnT elevation is based on NSM, renal failure or other concomitant diseases. Nevertheless, because coronary angiography was performed in only 15% of our patients and no reliable markers to distinguish MI from NSM were identified, MI was probably missed in a relevant number of patients who did not undergo coronary angiography.

Our study has several limitations. It is a retrospective observational study with probable selection bias and a relative small sample size. In particular, the decision to perform coronary angiography was made individually, and therefore the rate of coronary heart disease in those patients who did not undergo coronary angiography cannot be reliably estimated. Furthermore, some parameters were not available of all patients, which may have reduced the statistical significance.

To summarize, we identified an association of NIHSS and baseline hsTnT but not between specific brain areas and hsTnT when affected. This indicates that NSM may occur with high NIHSS scores. However, our analysis did not identify any factor that was specific for NSM or MI. None of the factors associated with elevated hsTnT turned out to be helpful to differentiate NSM and MI in the clinical setting. Accordingly, MI and NSM have to be taken into account in all patients with elevated baseline hsTnT levels. To solve the differential diagnosis ancillary investigations such as cardiovascular MR or coronary angiography or both may be required. A prospective study with systematic differentiation of MI and NSM using cardiovascular MR or coronary angiography in patients with elevated hsTnT might improve our understanding of the significance of elevated baseline hsTnT and its temporal changes.

Supporting information
S1 Dataset. Minimaldataset.
(SAV)

Acknowledgments
We thank Pietro Ballinari for statistical advice.

Author Contributions
Conceptualization: Laura Bickel, Heinrich P. Mattle, Simon Jung.
Data curation: Kai Liesirova, Eugenio Abela, Thomas Pilgrim, Laura Bickel, Thomas Meinel, Julia Meisterernst, Verma Rajeev, Hakan Sarikaya, Mirjam R. Heldner, Tomas Dobrocky, Erick Siqueira, Marwan El-Koussy, Urs Fischer, Jan Gralla, Marcel Arnold, Heinrich P. Mattle, Kety Hsieh, Simon Jung.
Formal analysis: Kai Liesirova, Eugenio Abela, Thomas Pilgrim, Julia Meistererst, Mirjam R. Heldner, Tomas Dobrocky, Urs Fischer, Jan Gralla, Kety Hsieh, Simon Jung.

Funding acquisition: Marcel Arnold, Heinrich P. Mattle, Simon Jung.

Methodology: Kai Liesirova, Eugenio Abela, Marwan El-Koussy, Urs Fischer, Heinrich P. Mattle, Kety Hsieh, Simon Jung.

Writing – original draft: Kai Liesirova, Eugenio Abela, Heinrich P. Mattle, Simon Jung.

Writing – review & editing: Eugenio Abela, Thomas Pilgrim, Laura Bickel, Thomas Meinel, Julia Meisterernst, Verma Rajeev, Hakan Sarikaya, Mirjam R. Heldner, Tomas Dobrocky, Erick Siqueira, Marwan El-Koussy, Urs Fischer, Jan Gralla, Marcel Arnold, Heinrich P. Mattle, Kety Hsieh, Simon Jung.

References

1. Anders B, Alonso a, Artemis D, Schäfer a, Ebert a, Kablau M, et al.: What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients? Cerebrovasc Dis 2013; 36:211–7. https://doi.org/10.1159/000353875 PMID: 24135532

2. Darki A, Schneck MJ, Agrawal A, Rupani A, Barron JT: Correlation of elevated troponin and echocardiography in acute ischemic stroke. J Stroke Cerebrovasc Dis 2013; 22:959–61. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.12.004 PMID: 2244712

3. Kerr G, Ray G, Wu O, Stott D, Langhorne P: Elevated troponin after stroke: a systematic review. Cerebrovasc Dis 2009; 28:220–6. https://doi.org/10.1159/000226773 PMID: 19571535

4. Nguyen H, Zaroff JG: Neurogenic stunned myocardium. Curr Neurol Neurosci Rep 2009; 9:486–91. PMID: 19818236

5. Dombrowski K, Laskowitz D: Cardiovascular manifestations of neurologic disease. Handb Clin Neurol 2014; 119:3–17. https://doi.org/10.1016/B978-0-7020-4086-3.00001-1 PMID: 24365284

6. Apak I, Ilhumur K, Tamam Y KN: Serum Cardiac Troponin T Levels as an Indicator of Myocardial Injury in Ischemic and Hemorrhagic Stroke Patients. Tohoku J Exp Med 2005; 112:803–15. https://doi.org/10.1093/bja/aeu046 PMID: 24638232

7. Viss CA, Kan G, Lie KI, Durrer D: Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients. Eur Heart J 1983; 4:333–7. PMID: 6617680

8. Heldner MR, Pilgrim T, Wustmann K, Hsieh K, Mattle HP, Arnold M, et al.: Acute Carotid T Occlusion in a Young Patient: Cryptogenic Origin? Stroke 2014; https://doi.org/10.1161/STROKEAHA.114.005388 PMID: 24876242

9. Ay H, Koroshetz WJ, Benner T, Vangel MG, Melinosky C, Arsaeva EM, et al.: Neuroanatomic correlates of stroke-related myocardial injury. Neurology 2006; 66:1325–9. https://doi.org/10.1212/01.wnl.0000206077.13705.6d PMID: 16525122

10. Scheitz JF, Endres M, Mochmann H-C, Audebert HJ, Nolte CH: Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. Int J Cardiol 2012; 157:239–42. https://doi.org/10.1016/j.ijcard.2012.01.055 PMID: 22326514

11. Song H-S, Back J-H, Jin D-K, Chung P-W, Moon H-S, Suh B-C, et al.: Cardiac troponin T elevation after stroke: relationships between elevated serum troponin T, stroke location, and prognosis. J Clin Neuro 2008; 4:75–83. https://doi.org/10.3988/jcn.2008.4.2.75 PMID: 19513307

12. Krause T, Werner K, Kiefer JB, Villringer K, Piper SK, Haesler KG, et al.: Stroke in right dorsal anterior insular cortex is related to myocardial injury. Ann Neurol 2017; 81:502–511. https://doi.org/10.1002/ana.24906 PMID: 28253544

13. Laowattana S, Zeger SL, Lima JAC, Goodman SN, Wittstein IS, Oppenheimer SM: Left insular stroke is associated with adverse cardiac outcome. Neurology 2006; 66:477–83. https://doi.org/10.1212/01.wnl.0000202684.29640.60 PMID: 16505298
16. Sykora M, Diedler J, Rupp A, Turcani P, Steiner T: Impaired baroreceptor reflex sensitivity in acute stroke is associated with insular involvement, but not with carotid atherosclerosis. Stroke 2009; 40:737–42. https://doi.org/10.1161/STROKEAHA.108.519967 PMID: 19118245

17. Berganzo K, Ciordia R, Gómez-Esteban JC, Tijero B, Agundez M, Velasco F, et al.: Tako-tsubo cardiomyopathy in a patient with bilateral lesions in the dorsal medulla. Clin Auton Res 2011; 21:65–7. https://doi.org/10.1007/s10286-010-0088-0 PMID: 20963467

18. Gilgen MD, Klimek D, Liesirova KT, Meisteremst J, Klinger-Gratz PP, Schroth G, et al.: Younger Stroke Patients With Large Pretreatment Diffusion-Weighted Imaging Lesions May Benefit From Endovascular Treatment. Stroke 2015; 46:2510–6. https://doi.org/10.1161/STROKEAHA.115.010250 PMID: 26251252

19. Jung S, Gilgen M, Slotboom J, El-Koussy M, Zubler C, Kiefer C, et al.: Factors that determine penumbral tissue loss in acute ischaemic stroke. Brain 2013; 136:3554–60. https://doi.org/10.1093/brain/awt246 PMID: 24065722

20. Jung S, Gralla J, Fischer U, Mono M-L, Weck A, Lüdi R, et al.: Safety of endovascular treatment beyond the 6-h time window in 205 patients. Eur J Neurol 2013; 20:865–71. https://doi.org/10.1111/ejn.12069 PMID: 23293861

21. Jung S, Mono ML, Fischer U, Galimani A, Findling O, De Marchis GM, et al.: Three-month and long-term outcomes and their predictors in acute basilar artery occlusion treated with intra-arterial thrombolysis. Stroke 2011; 42:1946–1951. https://doi.org/10.1161/STROKEAHA.110.606038 PMID: 21546481

22. Faiz KW, Thommessen B, Einvik G, Brekke PH, Omland T, Ranning OM: Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke. BMC Neurol 2014; 14:96. https://doi.org/10.1186/1471-2377-14-96 PMID: 24885286

23. Chalela JA, Ezzeddine MA, Davis L, Warach S: Myocardial injury in acute stroke: a troponin I study. Neurocrit Care 2004; 1:343–6. https://doi.org/10.1385/NCC:1:3:343 PMID: 16174932

24. Abdi S, Oveis-Gharan S, Sinaei F, Ghorbani A: Elevated troponin T after acute ischemic stroke: Association with severity and location of infarction. Iran J Neurol 2015; 14:35–40. PMID: 25874055